Frontiers in Drug Design and Discovery is a book series devoted to publishing the latest and the most important advances in drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The book series should prove to be of interest to all the pharmaceutical scientists involved in research in drug design and discovery. Each volume is devoted to the major advances in drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. The book series is available in print, online and CD editions.

Frontiers in Drug Design and Discovery is an eBook series devoted to publishing the latest and the most important advances in drug design and discovery. Eminent scientists have contributed chapters focused on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. This eBook series should prove to be of interest to all pharmaceutical scientists who are involved in research in drug design and discovery and who wish to keep abreast of rapid and important developments in the field. The seventh volume of this series brings together seven reviews covering chemotherapeutic agents, antimicrobials and phytochemicals. Some topics included in this volume are: 1. Metabolic pathways and chemotherapy drugs 2. Cardiotoxicity of cancer chemotherapy 3. Nanotherapeutics for infectious diseases 4. Natural sources of angiogenesis inhibitors …and much more.

Frontiers in Drug Design and Discovery is a book series devoted to publishing the latest and the most important advances in drug design and discovery. Eminent scientists have contributed chapters focused on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. This book series should prove to be of interest to all pharmaceutical scientists who are involved in research in drug design and discovery and who wish to keep abreast of rapid and important developments in the field.

Frontiers in Drug Design and Discovery Volume 9 is a book series devoted to publishing the latest and the most important advances in drug design and discovery. Eminent scientists have contributed chapters focused on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. This book series should prove to be of interest to all pharmaceutical scientists who are involved in research in drug design and discovery and who wish to keep abreast of rapid and important developments in the field. The ninth volume of this series brings together reviews covering topics related to the treatment of neoplasms, systems biology, respiratory diseases among others. Topics included in this volume are: -Prognostic biomarkers in prostate cancer -Chemoresistance in cancer cells -GPCRS in systems and synthetic biology -Mechanisms of action of ribavirin in different diseases -Carbon nanotubes and drug targets -The role of phosphatase I inhibitors in Minkowski spaces -Phosphodiesterase targeting for treating respiratory diseases

Frontiers in Drug Design and Discovery is a book series devoted to publishing the latest and the most important advances in drug design and discovery. Eminent scientists have contributed chapters focused on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. This book series should prove to be of interest to all pharmaceutical scientists who are involved in research in drug design and discovery and who wish to keep abreast of rapid and important developments in the field. The tenth volume of this series brings together reviews covering topics related to the treatment of neoplasms, systems biology, respiratory diseases among others. Topics included in this volume are: - Recombinant Protein Production: from Bench to Biopharming - Plant Virus Nanoparticles and Virus like Particles (VLPs): Applications in Medicine - MAO Inhibitory Activity Of 4, 5-Dihydro-1 HPyrazole Derivatives: A Platform To Design Novel Antidepressants - Flavonoids Antagonize Effects of Alcohol in Cultured Hippocampal Neurons: A Drug Discovery Study - Hybrid Smart Materials for Topical Drug Delivery: Application of Scaffolds

Frontiers in Drug Design and Discovery is a book series devoted to publishing the latest and the most important advances in drug design and discovery. Eminent scientists have contributed chapters focused on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. This book series should prove to be of interest to all pharmaceutical scientists who are involved in research in drug design and discovery and who wish to keep abreast of rapid and important developments in the field. Volume 11 of this series brings together reviews covering immunotherapy of sepsis, new antimalarials, and the medicinal use of onions for respiratory diseases, among other topics. Topics included in this volume are: - Heme-oxygenase and autophagy connected as a cytoprotective mechanism: potential therapeutic target - Development of recombinant therapeutic proteins in animal cells: Challenges and solutions - Artemisinin Analogues as a Novel Class of Antimalarial Agents: Recent Developments, Current Scenario and Future Perspectives - The effects of Allium cepa and their derivatives on respiratory diseases and the possible mechanisms of these effects - Immunotherapy of Sepsis

Frontiers in Drug Design and Discovery is a book series devoted to publishing the latest and the most important advances in drug design and discovery. Eminent scientists have contributed chapters focused on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. This book series should prove to be of interest to all pharmaceutical scientists who are involved in research in drug design and discovery and who wish to keep abreast of rapid and important developments in the field. Volume 12 of this series brings together reviews covering homology modeling and anti-infective drug discovery. Topics included in this volume are: - Homology Modelling: A Computational Tool in Drug Design and Discovery - Anti-trypanosomatid Drugs/Candidates in Clinical Trials: What's New and What's Missing? - Nitroheterocyclics As Anti-Tuberculosis Agents: An Overview - SARS-CoV-2 Protease Inhibitors of Natural Origin: Current Scenario and Future Prospects as Anti-COVID-19 Agents

The development of new erythropoietic stimulating agents (ESAs) has significantly increased in recent years. Researchers are focused on different and interesting concepts, namely, methods to increase half-life of erythropoietin (EPO), finding different routes of administration and new ESA or modified EPO molecules. Scientific literature presents evidence that EPO has other effects beyond erythropoietic stimulation. These pleiotropic effects of EPO appear to result from the existence of two different EPO receptors (EPOR) with different affinities for EPO. The discovery of new EPO actions beyond the hematopoietic system has opened a new field of investigation with these agents. Several molecules have been developed to present the protective action, without the activation of the hematopoietic system. These agents can be potentially used in several diseases of the brain/central and peripheral nervous system, eye, heart and kidney. This volume of Frontiers in Drug Discovery includes a revision of articles on erythropoiesis and EPO gene regulation, microRNAs and their potential contribution to the development of new therapeutic strategies, animal models for studying kidney disease-associated anemia as well as benefits/risks of ESA therapy. The biological effects of new ESA molecules, heparin-binding erythropoietin and of pHBSP, and the potential applications of ESA, are also elicited in this volume. This volume is, therefore, a useful reference for medicinal chemists and hematologists interested in drug development and medicine related to ESAs.

Major depressive disorder (MDD) is a prevalent, chronic, and recurring mental disorder. This disorder is a leading source of disability worldwide, and is associated with excess mortality rates. Currently approved antidepressants primarily enhance, or otherwise modulate monoaminergic neurotransmission, without curing the disease. Evidence indicates that only one third of patients with MDD achieve remission after treatment with a first-line antidepressant agent. Research in the past two decades has provided valuable insights into the pathophysiological understanding of MDD. However, there is an acknowledged ‘translational gap’ in the field, and few genuinely novel antidepressants have been approved for the treatment of MDD. The Search for Anti Depressants provides readers an in-depth picture of the main pathophysiological mechanisms responsible for the development of MDD in patients. Chapters in the volume focus on possible strategies to spur the discovery of novel antidepressants. This book is an indispensable reference for mental health care providers, students at both under-graduate and graduate levels, and neuroscientists interested in the neurobiology of MDD and recent advances towards the discovery of next generation antidepressants.

This book provides an update on heterocyclic compounds that serve as key components of anti-cancer agents administered in pre-clinical settings. Many of the compounds highlighted in the book are being actively investigated for the bioactive properties against a range of cancer cell lines. There is potential for heterocyclic compounds to design agents that can target specific molecules to treat different types of cancers. Chapters are contributed by experts in pharmaceutical chemistry and are written to give a general overview of the topic to readers involved in all levels of research and decision-making in pharmaceutical chemistry and anti-cancer drug design. Part 1 of the book set covers these topics: - Heterocyclic anticancer compounds derived from natural sources with their mechanism of action - The role of terpenoids as anticancer compounds: an insight into prevention and treatment - Recent advances in synthesis and anticancer activity of benzothiazole hybrids as anticancer agents - Structure-activity relationship studies of novel hybrid quinoline and quinolone derivatives as anticancer agents - Tetrazoles: structure and activity relationship as anticancer agents - Progress in nitrogen and oxygen-based heterocyclic compounds for their anticancer activity: an update (2017-2020)